| 1.17 0.01 (0.86%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.41 |
1-year : | 1.51 |
| Resists | First : | 1.2 |
Second : | 1.29 |
| Pivot price | 1.14  |
|||
| Supports | First : | 1.05 |
Second : | 0.88 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.15 |
| MA(100) : | 1.28 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.5 |
D(3) : | 58 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 1.89 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SLS ] has closed below upper band by 35.3%. Bollinger Bands are 66.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.19 | 1.19 - 1.19 |
| Low: | 1.13 - 1.13 | 1.13 - 1.14 |
| Close: | 1.16 - 1.17 | 1.17 - 1.18 |
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Wed, 17 Jul 2024
Investors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - Defense World
Tue, 18 Jun 2024
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely - Simply Wall St
Wed, 22 May 2024
Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth? - Yahoo Finance
Tue, 14 May 2024
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 14.2 (%) |
| Shares Short | 8,860 (K) |
| Shares Short P.Month | 7,650 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -84.6 % |
| Return on Equity (ttm) | -313.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.09 |
| PEG Ratio | 0 |
| Price to Book value | 6.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|